← All trials
NCT07195695
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2025
- Primary completion
- Feb 26, 2032
- Completion date
- Sep 2, 2036
- First posted
- Sep 29, 2025
- Last posted
- Nov 26, 2025
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.